NC-TANNER-PHARMA
8.3.2021 16:55:06 CET | Business Wire | Press release
Tanner Pharma Group (Tanner) today announced expansion of the LEUKINE Access Program (LeAP) as a channel for distribution of LEUKINE® (sargramostim) in international markets. LEUKINE®, approved by the US FDA in 1991 and now manufactured by Partner Therapeutics (PTx), is a recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) that stimulates the immune system and has been used in leukemia patients to reduce the risk of infection.
PTx recently announced that a clinical trial of Leukine® conducted in Belgium of hospitalized COVID-19 patients suffering from acute hypoxic respiratory failure requiring supplemental oxygen met the primary endpoint of significant improvement in lung function. Improvement in oxygenation of at least 33% or more from baseline was seen in 54% of patients on the LEUKINE® plus standard-of-care (SOC) arm versus 26% of patients on SOC (p=.0147).
Tanner provides a regulatory-compliant pathway to make LEUKINE® available in international markets. If a patient is in a country where LEUKINE® is not available commercially physicians may be able to have Leukine® imported for their patients through named patient supply via LeAP managed by Tanner.
“As demonstrated by these positive clinical trial results, LEUKINE® has the potential to help COVID-19 patients,” said Banks Bourne, CEO of Tanner Pharma Group. “Our team is incredibly honored to be trusted with this important role, and we are mobilized to help patients and clinicians around the world gain access.”
LEUKINE® is currently being assessed in a clinical trial in the United States (NCT04411680) to further measure impact on COVID-19 patients.
For more information about this program or to request access to LEUKINE®, please call +1 704 643 8989 or email leukine@tannerpharma.com
About Tanner Pharma Group
Tanner Pharma Group partners with biopharmaceutical companies to provide turn-key solutions that increase patient access to medicines around the world. With an unparalleled blend of local market knowledge and international supply chain expertise across more than 130 countries, Tanner provides tailored solutions to biopharmaceutical companies outside their core markets of focus. For more information, visit www.tannerpharma.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210308005639/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
I-Pulse Acquires CSI Technologies to Strengthen U.S. High-Energy Capacitor Manufacturing Capabilities18.3.2026 14:30:00 CET | Press release
I-Pulse Acquires California Capacitor Specialist CSI Technologies to Advance Disruptive Pulsed Power ApplicationsCSI Acquisition Secures Strategic Technologies Central to I-Pulse’s Pulsed Power Roadmap Co-Founder, Chairman, and CEO, Robert Friedland, and Co-Founder and Chief Technology Officer, Laurent Frescaline, of I-Pulse, the world leader in high pulsed power technologies, are pleased to announce the acquisition of CSI Technologies, Inc., the California-based manufacturer of high-energy, high-voltage capacitors serving industrial, medical, and defense applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260318099794/en/ The strategic acquisition enhances I-Pulse’s pulsed power development and U.S. manufacturing capabilities, particularly in mining, geothermal energy, mineral exploration, and water resource applications. By integrating CSI Technologies’ proven capacitor design and production expertise, I-Pulse str
Elliptic Integrates With Tempo, the Payments-First Blockchain18.3.2026 14:15:00 CET | Press release
Elliptic, the leader in digital asset decisioning, today announced full blockchain coverage for Tempo, the payments-first Layer-1 blockchain incubated by Stripe and Paradigm. With this integration, compliance and investigation teams gain full visibility into one of the most significant expansions of real-world financial activity onto blockchain infrastructure. "We're excited to have Elliptic providing compliance infrastructure on Tempo from day one. As payments move onchain at scale, builders and their customers need real-time tools to meet regulatory requirements without slowing down." – Nischay Upadhyayula, GTM, Tempo Tempo is a Layer-1 blockchain designed for real-world payments at scale, with sub-second finality and high throughput. Incubated by Stripe and Paradigm, Tempo is built for the transaction volumes that global commerce demands. Elliptic’s blockchain analytics platform is purpose-built to analyse on-chain data at this scale. “Tempo’s payment-specific blockchain infrastruct
RecVue Completes Acquisition of AiVidens18.3.2026 14:04:00 CET | Press release
Transaction advances RecVue RevOS into a unified revenue-to-cash Revenue Operating System RecVue, the leader in AI-powered billing and revenue management platforms for complex enterprise monetization, today announced it has completed the acquisition of AiVidens. By acquiring the cash management and collections platform, RecVue will enable enterprises to move beyond simple revenue automation to unify contract governance, billing, collections, revenue compliance, revenue sharing, and liquidity management all within a single revenue operating system. “This acquisition furthers our strategy to close the structural gap between revenue and cash,” said Nishant Nair, Founder and CEO of RecVue. “CFOs today are accountable not only for revenue accuracy, but for liquidity performance and working capital efficiency. With AiVidens, we are extending RevOS to connect commercial activity directly to cash realization.” While tasked with these widening responsibilities, enterprise CFOs struggle with dis
Blue Matter Launches People and Organization Practice to Help Biopharma Navigate Structural Shift18.3.2026 14:01:00 CET | Press release
Blue Matter today announced the launch of its People and Organization Practice, a dedicated capability designed to help life science companies build organizations that can perform through complexity - from enterprise transformation and M&A integration to talent strategy, learning, and workforce redesign. The launch reflects a central conviction: the biopharma industry is not experiencing a cyclical downturn but a structural shift. With more than 42,700 jobs cut across the sector in 2024–2025, unprecedented policy uncertainty, accelerating AI adoption, and intensifying portfolio pressure, organizations must transform all functions simultaneously, not sequentially, to remain competitive. A Proven Leader Across Transactions and Transformations Stacey Petrey brings more than 25 years of experience and a track record spanning more than 75 completed transactions. Stacey served as a Partner in PwC’s Deals practice where she focused on integrations, separations, value creation, and change mana
Deskpro Now Available on the AWS European Sovereign Cloud18.3.2026 14:00:00 CET | Press release
Deskpro has deployed its help desk platform on the AWS European Sovereign Cloud, extending access to AI-powered support for organizations that need to meet strict EU data residency and sovereignty requirements Today, Deskpro, provider of the secure AI-powered help desk platform, announced that it is a partner for the AWS European Sovereign Cloud, a new, independent cloud for Europe that is backed by strong technical controls, sovereign assurances, and legal protections designed to meet the needs of European governments and enterprises. Becoming an AWS European Sovereign Cloud partner strengthens Deskpro’s ability to support customers deploying environments within the AWS European Sovereign Cloud, and reinforces its commitment to supporting organizations for which data residency, governance, and regulatory alignment are non-negotiable. “European organizations face growing complexity around data sovereignty and regulatory compliance,” said Brad Murdoch, CEO of Deskpro. “By becoming an AW
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom